Hi Bucky,
The answer to your question: "why the safety committee hasn't already given permission for cohort 1 patients to move to cohort 3" is that the safety committee will review the safety of dose 2 (the higher dose - recently completed) before giving permission for the administration of an even higher dose of MPL to patients in cohort 3. In this sense, when cohort 1 finished is immaterial.
Cheers
Densy
Ann: Progress update on Phase 1/2 MND interim analysis, page-21
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $98.34M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $106.8K | 532.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 99579 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 102832 | 5 |
View Market Depth
| Last trade - 15.42pm 11/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |